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Abstract
Background: Administration of exogenous interferon-g (IFNg) aggravates the symptoms of multiple sclerosis (MS),
whereas interferon-b (IFNb) is used for treatment of MS patients. We previously demonstrated that IFNg induces
apoptosis of oligodendroglial progenitor cells (OPCs), suggesting that IFNg is more toxic to OPCs than IFNb. Thus
we hypothesized that a difference in expression profiles between IFNg-inducible and IFNb-inducible genes in OPCs
would predict the genes responsible for IFNg-mediated cytotoxic effects on OPCs. We have tested this hypothesis
particularly focusing on the interferon regulatory factors (IRFs) well-known transcription factors up-regulated by
IFNs.
Methods: Highly pure primary rat OPC cultures were treated with IFNg and IFNb. Cell death and proliferation were
assessed by MTT reduction, caspse-3-like proteinase activity, Annexin-V binding, mitochondrial membrane potential,
and BrdU-incorporation. Induction of all nine IRFs was comprehensively compared by quantitative PCR between
IFNg-treated and IFNb-treated OPCs. IRFs more strongly induced by IFNg than by IFNb were selected, and tested
for their ability to induce OPC apoptosis by overexpression and by inhibition by dominant-negative proteins or
small interference RNA either in the presence or absence of IFNg.
Results: Unlike IFNg, IFNb did not induce apoptosis of OPCs. Among nine IRFs, IRF1 and IRF8 were preferentially
up-regulated by IFNg. In contrast, IRF7 was more robustly induced by IFNb than by IFNg. Overexpressed IRF1
elicited apoptosis of OPCs, and a dominant negative IRF1 protein partially protected OPCs from IFNg-induced
apoptosis, indicating a substantial contribution of IRF1 to IFNg-induced OPC apoptosis. On the other hand,
overexpression of IRF8 itself had only marginal proapoptotic effects. However, overexpressed IRF8 enhanced the
IFNg-induced cytotoxicity and the proapoptotic effect of overexpressed IRF1, and down-regulation of IRF8 by siRNA
partially but significantly reduced preapoptotic cells after treatment with IFNg, suggesting that IRF8 cooperatively
enhances IFNg-induced OPC apoptosis.
Conclusions: This study has identified that IRF1 and IRF8 mediate IFNg-signaling leading to OPC apoptosis.
Therapies targeting at these transcription factors and their target genes could reduce IFNg-induced OPC loss and
thereby enhance remyelination in MS patients.
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Persistent demyelination often follows recurrent inflam-
mation in multiple sclerosis (MS), even though oligo-
dendroglial progenitor cells (OPCs) are present in the
adult CNS as a potential source of oligodendrocytes for
remyelination after loss of myelin [1-3]. As a pathologi-
cal mechanism underlying this remyelination failure,
accumulating evidence indicates that interferon-g (IFNg),
the only type II IFN secreted into the lesions by infil-
trating T helper 1 (TH1) cells and natural killer cells,
induces cytotoxic effects on OPCs, and inhibits their dif-
ferentiation, leading to failure in de novo myelination by
OPCs [4-9]. We also demonstrated in our previous
study that actively proliferating OPCs are far more sus-
ceptible to cytotoxic effects of IFNg than are post-
mitotic mature myelinating oligodendrocytes [10]. In
contrast to IFNg,i n t e r f e r o n - b (IFNb), a type I IFN, is
used successfully to reduce relapse rates in relapsing
remitting MS [11]. However, though IFNb has minimal
adverse effects on proliferation, migration and differen-
tiation of oligodendrocytes in vitro [12,13], it does inhi-
bit remyelination after cuprizone-induced demyelination
in vivo [14]. Given the extensive overlap in type I and
type II IFN signaling pathways, our goal in the present
study was to determine what molecular mechanisms are
responsible for the much greater OPC toxicity of IFNg
than IFNb.
The janus kinase (JAK)/signal transducer and activator
of transcription (STAT) pathway has been well-studied
as a principal intracellular signaling pathway activated
by IFNs (Reviewed in [15]). Binding of IFNg to the type
II IFN receptor results in the rapid autophosphorylation
and activation of the receptor-associated JAK1 and
JAK2, which in turn activates cytoplasmic STAT1 by
phosphorylation at Tyr 701. Activated STAT1 proteins
form homodimers, which translocate into the nucleus,
and initiate transcription by binding to a specific motif,
known as the IFNg-activated site (GAS), in the promo-
ters of various IFN-stimulated genes (ISGs). IFNb uti-
lizes another receptor, the type I IFN receptor,
associated with JAK1 and tyrosine kinase 2 (TYK2), and
regulates formation of the heterotrimeric transcription
complex, interferon-stimulated gene factor 3 (ISGF3),
composed of the activated forms of STAT1 and STAT2,
and IRF9/ISGF3g. ISGF3 recognizes the IFN-stimulated
response element (ISRE) which is distinct from the
GAS, and activates transcription of another set of ISGs.
Although there is a substantial overlap between IFNb-
inducible and IFNg-inducible ISGs stemming from their
common dependence on activation of STAT1 [16], we
hypothesized that IFNg-mediated cytotoxic effects on
OPCs are attributable to ISGs which are differently
induced in OPCs by IFNg than by IFNb.
As an example of the ISGs which are differently
induced between IFNg and IFNb,w ep r e v i o u s l ye x a m -
ined IFN-mediated transcriptional induction of major
histocompatibility complex class II (MHC-II) molecules
in the oligodendroglial lineage [17]. Surface expression
of MHC-II becomes detectable in OPCs after treatment
with IFNg,w h e r e a sI F N b fails to induce expression of
MHC-II. Our results indicated that the distinct differ-
ence in transcriptional activation of interferon regulatory
factor 1 (IRF1) between IFNg and IFNb is attributed to
the difference in subsequent MHC-II expression. Thus,
IRF1 is also a promising example of the ISGs responsi-
ble for IFNg-mediated cytotoxic effects in OPCs. In
agreement with this idea, involvement of IRF1 in IFNg-
induced OPC apoptosis has recently been reported [18].
IRF1 was originally isolated as a transcriptional activa-
tor of the IFNb gene in response to viral infection
[19,20]. IRF1 and eight other subsequently identified fac-
tors share a highly-conserved amino-terminal DNA
binding domain (DBD) with five conserved tryptophan
repeats, and thereby constitute a family of transcription
factors, termed the IRF family (Reviewed in [21-24]).
The DBD forms a helix-turn-helix domain and recog-
nizes similar, if not identical, DNA motifs containing
the consensus IRF recognition sequence, 5’-AANN-
GAAA-3’ [25]. IRF2, which shares the highly homolo-
gous DBD with IRF1, is considered a transcriptional
repressor for IRF1-mediated transcription by competing
for the same cis elements [19,26,27]. In addition, most
of the members, except IRF1 and IRF2, have an IRF
association domain (IAD) at the C-terminal region,
through which they interact with other members or
other transcription factors. Despite the possible func-
tional overlap and interplay among members of the IRF
protein family, however, there have been only a few stu-
dies on the IRF family members in the oligodendroglial
lineage [28], particularly with respect to their roles in
IFNg-mediated and IFNb-mediated signaling [17]. In
this study, using primary cultures of highly pure OPCs
from rats, we performed a comprehensive analysis of all
members of the IRF family in OPCs in response to IFNg
and IFNb, and examined the synergistic roles for IRF1
and IRF8 (also known as interferon consensus sequence
binding protein (ICSBP)), in IFNg-induced OPC
apoptosis.
Methods
Reagents and chemicals
All reagents and culture media used in this study were
purchased from SIGMA (St. Louis, MO, USA) and Invi-
trogen (Carlsbad, CA, USA), respectively, except for the
following products: Human recombinant fibroblast
growth factor 2 and platelet-derived growth factor A
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USA); rabbit anti-IRF1 and anti-IRF2 antibodies were
from Santa Cruz Biotechnology (Santa Cruz, CA, USA),
and mouse anti-glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) antibodies were from Chemicon
(Temecula, CA, USA). Rabbit anti-IRF8 antibody was
produced by Ozato’s laboratory. Small interfering RNA
(siRNA) for IRF2 (siRNA ID: s220597), IRF8 (siRNA ID:
s146232), and Negative control siRNA were from
Ambion (Austin, TX, USA).
Mixed glial culture
Primary mixed glial cultures from rats were prepared
as reported previously [29]. Briefly, whole brains were
dissected from 0 to 2-day-old Lewis rats, and sub-
merged in ice-cold Leibovitz’sL - 1 5m e d i u m .U n d e ra
dissecting microscope, olfactory bulbs, cerebral cortices
and hindbrains were removed. After cleaning off
meninges and vessels including choroidal plexus, the
remaining brain tissues were cut into small chunks
with a 21-gauge needle, and digested by 0.0625% (w/v)
t r y p s i ni nC a
2+ and Mg
2+-free Hank’s Balanced Salt
Solution (HBSS) for 20 min. Dissociated cells were
obtained by passing the softened chunks through a
1 ml pipette tip several times, and collected by centri-
fugation at 365 xg for 5 min. The cells were resus-
pended in minimum essential medium alpha
containing 5% (v/v) fetal bovine serum and 5% (v/v)
calf serum, and plated onto a 10 cm culture dish. One
day after plating, attached cells (designated as pas-
sage 0) were washed with HBSS to remove serum, and
thereafter maintained in the medium (GM), a 3:7 mix-
ture (v:v) of B104 neuroblastoma-conditioned medium
and the N1 medium (high glucose Dulbecco’s modified
Eagle’s medium supplemented with 6 mM L-glutamine,
10 ng/ml biotin, 5 μg/ml insulin, 50 μg/ml apo-trans-
ferrin, 30 nM sodium selenite, 20 nM progesterone
and 100 μM putrescine as final concentrations). Cul-
tures were fed with fresh GM medium every other day
for approximately 5 days, at which time the proliferat-
ing glial cells were almost confluent.
Immunopanning for purification of A2B5
+ rat OPCs
The mixed glial cultures were washed with Ca
2+ and
Mg
2+-free HBSS, suspended in the N1 medium contain-
ing 0.1% (w/v) BSA, and plated and incubated on nega-
tive immunopanning plates coated with RAN-2 antibody
for 30 min at 37°C to exclude RAN-2-positive cells [29].
Following two rounds of this negative selection, nonad-
herent cells were transferred to the A2B5 positive pan-
ning plates. After the serial immunopanning, purified
cultures contained more than 95% of OPCs which were
A2B5-positive, O4-negative, and glial fibrillary acidic
protein-negative.
Immunocytochemistry
Cells cultured on poly-D-lysine-coated coverslips were
incubated with A2B5 hybridoma supernatants (undi-
luted) at room temperature for 30 min. After washing
with phosphate-buffered saline (PBS), cells were fixed
with 4% paraformaldehyde at room temperature for
15 min, and then permeabilized with 100% methanol at
-20°C for 15 min. For IRF8 staining, cells were incu-
bated with anti-IRF8 antibody diluted at 1:50 in PBS
containing 5% normal goat serum and 0.03% Triton-X
100 at room temperature for 2 h, after permeabilization
by 100% methanol. After incubation with fluorophore-
conjugated secondary antibodies (1:50, v:v) in PBS at
room temperature for 30 min, nuclei were counter-
stained with 4,6-diamidio-2-phenylindole (0.5 μg/ml) for
10 min, and then the coverslips were mounted on slide
glasses with VectorShield (Vector laboratory, Burlin-
game, CA, USA).
Immunoblots
Protein lysates were prepared in the lysis buffer as
described previously [10]. Twenty μgo fp r o t e i nf r o m
each sample were size-fractioned by SDS-polyacrylamide
gel electrophoresis, transferred onto a nitrocellulose
membrane (Schleicher & Schnell, Keene, NH, USA) and
probed with primary antibodies for IRF1 (1:400, v:v) and
IRF8 (1:5000, v:v) for 1 h. Full range recombinant
Rainbow Molecular Weight Markers (Amersham Bios-
ciences, Piscataway, NJ, USA) were used as a reference
for molecular sizes. Immunoreactive signals were
detected by enhanced chemiluminescence according to
the manufacture’s protocol (Amersham Biosciences).
Equal protein loading was confirmed by subsequent
probing with the mouse monoclonal antibody against
GAPDH in each experiment.
Caspase activity assay
Cells were homogenized in lysis buffer (100 mM HEPES;
10% (w/v) sucrose; 0.1% (w/v) 3-[(3-cholamidopropyl)
dimethylammonio]-1-propanesulfonate; 10 mM dithio-
threitol; 1 mM EDTA; 1 mM phenylmethylsulfonyl
fluoride, 2 μg/ml aprotinin; 1 μg/ml pepstatin; 5 μg/ml
leupeptin) [30]. The protein lysates were stored at -80°C
until use as a 1:1 (v:v) mixture with glycerol. Caspase
activity was measured by a fluorometric method; protein
samples (10 μg) were incubated with the fluorogenic
substrate, acetyl-Asp-Glu-Val-Asp-a-(4-methylcou-
maryl-7-amide) (12.5 μM) (Ac-DEVD-AMC, Peptides
international, Luoisville, KY, USA) in 250 μl of the lysis
buffer, and cleavage of Ac-DEVD-AMC was monitored
by a multiplate spectrofluoromater, Gemini EM (Mole-
cular devices, Sunnyvale, CA, USA) for 60 min at 25°C.
The DEVD-cleavage activity was expressed as delta RFU
(relative fluorescence unit)/μg protein/h.
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OPCs cultured in 60 mm dishes were exposed to a 4 h
BrdU pulse (10 μM) just prior to harvesting. The trypsi-
nized cells were collected in GM and resuspended in 1.5
ml PBS. After fixation by 70% (v/v) ethanol at -20°C for
overnight, 5 × 10
4 cells were washed with 1 ml of the
washing buffer (0.1% (w/v) BSA in PBS), and denatured
by resuspension in 2N HCl at room temperature for
20 min. After resuspending once more in washing buf-
fer, the cells were incubated in 0.1 M sodium borate at
room temperature for 2 min to neutralize any residual
acid. Cells that had incorporated BrdU following incuba-
tion were identified by incubation with a fluorescein iso-
thiocyanate (FITC)-conjugated mouse anti-BrdU
monoclonal antibody at room temperature for 20 min in
dilution buffer (0.1% (w/v) BSA, 0.5% (v/v) Tween-20 in
PBS) followed by another resuspension in washing buf-
fer. The labeled cells were detected in the green (FL1)
channel of a flow cytometer, CyAn-ADP (Dako cytoma-
t i o n ,C a r p i n t e r i a ,C A ) .F I T C - c o n j u g a t e dm o u s em o n o -
clonal IgG1 was used as isotype control.
MTT assay
Cell viability was estimated by the enzymatic conversion
of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) to formazan crystals in live cells.
Formazan was dissolved in dimethyl sulfoxide at 90 min
after addition of MTT (0.5 mg/ml) to the culture med-
ium, and quantified by a spectrophotometer or a micro-
plate reader at 560 nm.
Annexin-V and propidium iodide binding assay
The OPC cultures were maintained in 60 mm dishes
and subjected to various experimental treatments. At 0,
24, and 48 h after these treatments, the culture medium
containing detached dead cells was collected, and the
attached cells were washed once with 2 ml of Ca
2+ and
Mg
2+-free HBSS. The attached cells were removed from
the plate by exposure to 0.5 ml of 0.05% trypsin at 37°C
for 2 min, suspended in 2 ml of GM with 625 μg/ml
trypsin inhibitor, and collected into a 15 ml tube
together with the saved medium and the Ca
2+ and Mg
2
+-free HBSS used for wash. After centrifuge at 520 xg
for 10 min, the pellet was resuspended into 0.4 ml of
binding buffer (0.1 M HEPES, pH 7.4; 140 mM NaCl;
2.5 mM CaCl2;0 . 4 5 %( w / v )D-glucose). Five μlo fF I T C -
conjugated annexin-V solution and propidium iodide
(PI; 8 μg/ml at final concentration) were added into
0.1 ml of the cell suspension. After incubation at room
temperature for 15 min in the dark, 0.3 ml of the bind-
ing buffer was added to the cell suspension. To deter-
mine the absolute number of cells in each preparation,
Flow-Count™ fluorospheres were added at a concentra-
tion of 19 beads/μl just before flow cytometry by CyAn-
ADP (DakoCytomation, Carpinteria, CA, USA). Fluores-
cence of annexin-V-FITC and PI were detected in FL-1
and FL-4 channels, respectively. Gatings and data acqui-
sition and analysis were carried out using Summit soft-
ware (DakoCytomation) as described previously [10].
Cell death and loss of mitochondrial membrane
potential assay
Rat OPCs cultured in 24-well plates were treated with
the GM or the GM supplemented with IFNg for 12, 18,
and 24 h. Prior to collection, cells were incubated with
tetramethylrhodamine ethyl ester (TMRE, 0.1 μM) at
37°C for 30 min. Then, culture medium containing dead
cells was collected, and cells were washed once with
0 . 5m lo ft h eC a
2+ and Mg
2+-free HBSS. Attached cells
were removed with 150 μlo f0 . 0 5 %t r y p s i nf o r1m i n ,
suspended in 1 ml of the GM, and collected into a
15-ml tube together with the saved medium and the
Ca
2+ and Mg
2+-free HBSS used for washing. After cen-
trifugation with 1500 rpm for 5 min, the supernatant
was aspirated and the pellet was kept on ice. Pellets
were resuspended with 0.5 ml PBS containing 5 μM
DAPI and 0.1% BSA immediately prior to analysis by
flow cytometry employing a Cyan-ADP Flow Cytometer
(DakoCytomation). Live and dead cell populations were
gated as described previously [10], and TMRE and DAPI
were detected in the FL-2 and the FL-6, respectively.
Real-time PCR
Real-time PCR analyses were performed by MX3005P
(Stratagene, La Jolla, CA, USA) using TaqMan
® Assay-
on-Demand™ assay kits (assay nos.: Rn00561424_m1,
Mm00515204_m1, Rn01764369_m1, Rn01435145_m1,
Rn01500522_m1, Rn01762216_g1 and Rn01751474_m1
for detection of IRF1, IRF2, IRF3, IRF4, IRF5, IRF8 and
interferon gamma induced GTPase (IGTP) cDNA,
respectively) [17]. For detection of IRF6, IRF7, and IRF9
cDNA, each set of primers and a probe was obtained
from Applied Biosystems as a Custom TaqMan
® Gene
Expression Assay, because the kits for these cDNA were
not available at the time of these experiments. For stan-
dardization, GAPDH cDNA levels were quantified with
TaqMan Rodent GAPDH Control Reagents according to
the manufacturer’s instructions, and the absolute cDNA
amounts were expressed as ratios to GAPDH cDNA.
We present representative data from at least two inde-
pendent analyses for each mRNA.
Plasmid construction
For the forced expression vectors, the open reading
frame of rat IRF1 or IRF8 was inserted in the pcDNA3.1
mammalian expression vector followed by the internal
ribosome entry site (IRES) and humanized Renilla reni-
formis green fluorescent protein (hrGFP, Stratagene) in
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flow cytometry or by fluorescence microscopy. The
expression vector for the dominant-negative form of
IRF1 (IRF1DN-hrGFP) and was constructed by insert-
ing the coding sequence of truncated rat IRF1 (amino
acids 1 to 144) into the pcDNA3.1 mammalian expres-
sion vector. The truncated IRF1 coding sequence was
fused to hrGFP in frame with a spacer sequence, Pro-
Gly-Gly-Gly-Gly-Pro (P4GP) hinge, in order to facili-
tate identification of transfected cells and to evaluate
the intracellular localization and stability of the domi-
nant negative protein. For forced double expression of
IRF1 and IRF8, the expression construct for IRF8 lack-
ing hrGFP reporter (PCMV-IE-IRF8-pA) was prepared
by inserting the open reading frame of rat IRF8 into
pcDNA3.1.
Transfection by electroporation
Trypsinized OPCs (2 × 10
6) were resuspended in 100 μl
of N1 medium with 10 μgp l a s m i dD N Ao r2μM
siRNA, and put into a 2 mm cuvette. A square pulse
with 110 mV for 25 msec was applied to the mixture of
cells and plasmid DNA with BioRad GenePulser Xcell
(BioRad, Hercules, CA, USA). Cells were resuspended
into GM, plated on 24 well plates, and subjected to
further experimental procedures.
Statistical analysis
Data are presented as mean ± SD unless otherwise
noted. Statistical significance was determined by two-
tailed ANOVA followed by Student-Newman-Keuls post
hoc test.
Results
IFNb is far less cytotoxic to OPCs than IFNg
IFNg significantly reduced the viability of purified
A2B5-positive OPCs to 32 ± 5% of the controls at 48 h
as reported in our prior study [10]. In contrast, IFNb
decreased the viability only to 91 ± 8% of the controls
at 1 kU/ml, a concentration sufficient to exert maximum
biological effects in various cell types [13,31,32]
(Figure 1G). IFNb failed to protect OPCs from IFNg-
induced cytotoxicity when IFNb and IFNg were added
simultaneously (Figure. 1G). IFNb did not alter surface
expression of A2B5 or the typical OPC morphology
(Figure. 1A-F).
Cytotoxicity of IFNg to OPCs consists of increase in
apoptosis and delay in G1/S transition of the cell cycle
[10]. Double staining with Annexin-V-FITC and PI
revealed that IFNb did not increase numbers of prea-
poptotic and dead cells compared to the control OPC
cultures, whereas preapoptotic cells became detectable
from 24 hr, and dead cells were significantly increased
at 48 h in the IFNg-treated OPC cultures (Figure.
2A, B). Caspase-3-like protease activity was significantly
induced by IFNg as early as 24 h, but not by IFNb even
at 48 h (Figure. 2C). These results indicated that, unlike
IFNg, IFNb did not enhance OPC apoptosis.
This far less proapoptotic effect of IFNb on OPCs was
not a consequence of less equivalent biological activity
of IFNb at 1 kU/ml compared to IFNg at 100 ng/ml.
First, a higher concentration of IFNb,3k U / m l ,a l s o
failed to induce caspase-3-like protease activity in OPCs
(Figure. 2D). Second, as far as determined by transcrip-
tional induction of IFNg induced GTPase (IGTP), IFNb
at 0.3 kU/ml or higher was sufficient to induce maximal
levels of IGTP mRNA (Figure. 2E). Third, based on the
standard anti-viral assay to measure the biological activ-
ities of IFNs [33], 100 ng/ml IFNg corresponds to
approximately 0.1 to 1 kU/ml, which is almost compar-
able to the biological unit of IFNb used in this study.
We therefore compared the effects of IFNg and IFNb at
Figure 1 IFNb is far less toxic to OPCs than IFNg. Phase-contrast
images (A-C) and immunocytochemistry for A2B5 (D-F) of rat OPCs
treated with GM alone (A, D), GM plus IFNb (1 kU/ml) (B, E)o rG M
plus IFNg (100 ng/ml) (C, F) for 48 h. G, Viability of OPCs cultured
with GM (control), GM supplemented with IFNb (IFNb), IFNg (IFNg),
or both (IFNg + IFNb) was measured by MTT assay at 48 h after
treatment. ** Indicates p < 0.01 compared with control. ** Indicates
p < 0.01 compared with control or in comparison between the two
groups indicated.
Horiuchi et al. Journal of Neuroinflammation 2011, 8:8
http://www.jneuroinflammation.com/content/8/1/8
Page 5 of 16100 ng/ml and 1 kU/ml, respectively, in further
experiments.
IFNg has been shown to inhibit cell cycle progression
in OPCs as well [10]. Cells were exposed to a 4 h BrdU
pulse immediately prior to fixation at 24 and 48 h after
treatments with IFNb or IFNg. The results confirmed
that both IFNg and IFNb significantly slowed progression
of the cell cycle (p < 0.01) at 24 and 48 h. Percentages of
BrdU-positive cells were significantly lower in the OPCs
treated with IFNg than those treated with IFNb at 48 h,
indicating that IFNb did inhibit cell cycle progression in
OPCs, but to a lesser extent than IFNg (Figure. 3).
Depolarization of the mitochondrial membrane potential
precedes IFNg-induced OPC apoptosis
Depolarization of the mitochondrial inner membrane is
one of the earliest hallmarks of apoptosis in many cell
types [34,35]. We identified preapoptotic OPCs with
depolarized mitochondria in the IFNg- and IFNb-treated
OPC cultures by live cell staining with both TMRE and
DAPI followed by flow cytometry. The number of prea-
poptotic cells with depolarized mitochondria but retain-
ing an intact plasma membrane (TMRE
-/DAPI
- cells)
was significantly increased in OPC cultures treated with
IFNg as early as 18 h after treatment, confirming that
Figure 2 Unlike IFNg,I F N b does not induce OPC apoptosis. A-B, Numbers of Annexin-V
+/PI
- (preapoptotic) cells and Annexin-V
+/PI
+ (dead)
OPCs after treatment with IFNb or IFNg for 24h and 48 h. Annexin-V
-/PI
- (live), preapoptotic, and dead cells were counted by flow cytometry,
and shown as percentages of averaged live cell numbers in control at 24 h. C, Caspase-3-like protease activity was measured with the
fluorogenic substrate, Ac-DEVD-MCA, in the protein lysates of OPCs treated with GM alone (control, open circles), IFNb (closed triangles) or IFNg
(closed circles) for 12, 24, and 48 h. ** indicates p < 0.01 compared with control or in comparison between the two groups indicated. D-E,
Dose-dependent effects of IFNb on induction of caspase-3-like proteinase activity and IGTP mRNA in OPCs. OPCs were treated with IFNb at 0,
0.3, 1, and 3 kU/ml for 24 h, and activity of caspase-3-like proteinase (D) and IGTP mRNA (E) were quantified.
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OPC apoptosis. In good agreement with the results of
the viability and caspase activity assays, however, prea-
poptotic OPCs did not increase in the cultures treated
with IFNb (Figure. 4).
IRF1 and IRF8 are preferentially up-regulated in OPCs
treated with IFNg compared to those treated with IFNb
IFNg induces OPC apoptosis, while IFNb does not. We
hypothesized that, although IFNb and IFNg transcrip-
tionally up-regulate substantially overlapping ISGs [16],
there must be some critical difference between IFNg-
inducible and IFNb-inducible gene sets that is responsi-
ble for IFNg-induced apoptosis of OPCs. Among
hundreds of ISGs, some members of the IRF protein
family are immediate transcriptional targets of inter-
feron-mediated JAK/STAT signaling, and subsequently
control induction of downstream ISGs as transcription
regulators [21-24]. Indeed, wep r e v i o u s l yd e m o n s t r a t e d
that IRF1 and IRF9 transcriptional kinetics differ
between IFNg-treated and IFNb-treated OPCs [17].
IFNg elicited a more than 70-fold sustained elevation of
IRF1 mRNA from the basal levels in OPCs. In contrast,
IFNb-mediated up-regulation of IRF1 mRNA was transi-
ent even in the continuous presence of IFNb, falling to
less than one tenth of the sustained levels induced by
IFNg at 24 h. We extended this analysis to other mem-
bers of the IRF protein family to obtain a comprehensive
view of differential transcriptional regulation of all
k n o w nI R F si nr e s p o n s et oI F N g and IFNb, because at
least some members are able to heterodimerize [36-38].
The quantitative PCR results demonstrated that members
of the IRF protein family in OPCs could be classified into
three groups in terms of their distinctive patterns of tran-
scriptional induction by IFNg and IFNb; 1) IRF1 and IRF8
were preferentially up-regulated by IFNg compared with
IFNb (Figure. 5A), 2) IRF7 was preferentially up-regulated
by IFNb compared with IFNg (Figure. 5B), and 3) IRF2 to
IRF6 and IRF9 were similarly regulated or not regulated
by IFNg and IFNb, with the basal levels of the transcripts
being IRF2 > IRF3 > IRF9 > IRF6 > IRF5 (Figure. 5C, The
results of IRF5 are not shown.). IRF4 mRNA was below
the detection limit in OPCs even in the presence of IFNs.
We therefore focused on roles for IRF1 and IRF8 in IFNg-
induced apoptosis of OPCs in this study, because IRF1
mRNA and IRF8 mRNA were up-regulated within 1 hr
after addition of IFNg, and remained at more than 10-fold
higher levels than those induced by IFNb until at least
24 h (Figure. 5D). Immunoblotting for IRF1 and IRF8 pro-
teins also confirmed selective up-regulation of these pro-
teins in the IFNg-treated OPC cultures (Figure. 5E).
IRF1 mediates IFNg-induced OPC apoptosis
We examined the effects of forced expression of either
IRF1 or IRF8 on OPC viability. Since transient transfec-
tion of primary rat OPCs generally demonstrates limited
efficiency, we used the dual expression constructs
PCMV-IE-IRF1-IRES-hrGFP-pA and PCMV-IE-IRF8-
IRES-hrGFP-pA in order to discriminate transfected cells
from untransfected cells with the aid of coexpressed
hrGFP in the transfected cells. PCMV-IE-IRES-hrGFP-
pA was employed as control (Figure. 6). These dual
expression constructs and the conventional cell death
assay depending on the membrane-impermeable DNA-
binding dye DAPI enabled us to count preapoptotic cells
(TMRE
-/DAPI
- cells) in either hrGFP
+ (transfected) or
hrGFP
- (untransfected) population by flow cytometry
with the gating strategy shown in Figure. 7B. Overexpres-
sion of IRF1 significantly increased the number of prea-
poptotic cells in the transfected population at 6 and 24 h
after transfection. On the other hand, overexpression of
IRF8 resulted in a significant increase in TMRE
-/DAPI
-/
hrGFP
+ cells at 6 h, although this effect was no longer
o b s e r v e da t2 4h .T h e r ew a sn os i g n i f i c a n ti n c r e a s ei n
preapoptotic cells in the untransfected (hrGFP
-)p o p u l a -
tion, which could be used as an internal control, further
validating these results (Figure. 7C). Moreover, total live
(hrGFP
+/DAPI
-) OPCs overexpressing IRF1 were
reduced by approximately 50% from 6 to 24 h after trans-
fection (Figure. 7D). These results indicate that upregula-
tion of IRF1 protein is sufficient for activation of the
apoptotic pathway in OPCs, but that up-regulation of
IRF8 protein alone is not.
To further confirm the proapoptotic effects of IRF1 on
OPCs, we overexpressed a fusion protein of the IRF1
DNA-binding domain and hrGFP as a dominant negative
Figure 3 IFNb inhibits progression of the cell cycle, though to
a lesser extent than IFNg. BrdU-incorporation of OPCs incubated
with IFNb (1 kU/ml, IFNb) or IFNg (100 ng/ml, IFNg) for 24 (open
bars) and 48 h (closed bars). OPCs were exposed to a 4 h-BrdU
pulse immediately before fixation. ** Indicates p < 0.01 compared
with control or in comparison between the two groups indicated.
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Page 7 of 16form of IRF1 (IRF1DN-hrGFP) in OPCs. OPCs were trea-
ted with IFNg at 24 h after transfection, and the number
of preapoptotic (TMRE
-/DAPI
-) cells in either hrGFP
+ or
hrGFP
- population was measured at 24 h after addition of
IFNg (Figure. 8A). Fluorescence microscopy demonstrated
that the IRF1DN-hrGFP protein was localized in the
nuclei of OPCs (Figure. 6C). Preapoptotic cells were par-
tially but significantly reduced in the OPCs expressing
IRF1DN-hrGFP at 24 h after addition of IFNg, compared
to the OPCs expressing hrGFP alone (Figure. 8B). These
results confirmed that inhibition of functional IRF1 by
IRF1DN-hrGFP protects OPCs from IFNg-induced
apoptosis, and that IRF1 is one of the ISGs that principally
mediate IFNg-induced OPC apoptosis.
IRF8 enhances IFNg-induced apoptosis of OPC
Although overexpression of IRF8 itself was not sufficient
to induce OPC apoptosis, it remained to be clarified
whether overexpressed IRF8 enhanced IFNg-induced
OPC apoptosis. To examine this, OPCs were transfected
with PCMV-IE-IRF8-IRES-hrGFP-pA, and then treated
with IFNg at 24 h after transfection. Numbers of prea-
poptotic (TMRE
-/DAPI
-) cells were significantly
increased in IRF8 overexpressing OPCs, compared with
Figure 4 IFNg, but not IFNb, depolarizes OPC mitochondria prior to loss of plasma membrane integrity. Representative histograms of
TMRE signals in DAPI-negative OPCs at 24 h after treatment with GM alone (control, A), IFNb (B)o rI F N g (C). More TMRE
-/DAPI
- OPCs were detected in
the gated area (R3) in the cultures treated with IFNg for 24 h compared to control and IFNb-treated cultures. D,T M R E
-/DAPI
- OPCs became detectable
between 12 and 18 h after treatment with IFNg (closed circle). In contrast, GM alone (control, open circles) or IFNb (closed triangles) did not increase this
population until 24 h after treatment. ** Indicates p < 0.01 compared with control.
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Page 8 of 16Figure 5 IRF1 and IRF8 are preferentially up-regulated in OPCs treated with IFNg. A-C, Quantitative analysis of induction of IRF1, IRF2, IRF3,
IRF6, IRF7, IRF8, and IRF9 mRNA in OPCs before (Cnt 0 h) and at 24 h after incubation with IFNg (100 ng/ml, G 24 h), IFNb (1 kU/ml, B 24 h), or
medium alone (Cnt 24 h). Each data point was from at least 3 independent experiments. Note that the data are plotted as ratios to copy
numbers of GAPDH cDNA on a logarithmic scale. ** Indicates p < 0.01 compared with control at 24 h (Cnt 24 h). D, IRF1 and IRF8 mRNA in
OPCs were quantified by real-time PCR at 1, 3, 6, 12, and 24 h after addition of GM alone (control, open circle), IFNg (100 ng/ml, closed circle) or
IFNb (1 kU/ml, closed triangle). For IRF8, basal IRF8 mRNA levels in the two RNA samples of spleen are shown as positive control (open
triangles). At time 0, data from controls are only shown. E, Induction of IRF1 and IRF8 proteins in OPCs was examined at 24 h after treatment
with IFNg and IFNb by immunoblotting.
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Page 9 of 16those transfected with the control vector, at 24 h after
addition of IFNg (Figure. 8B).
We further tested whether down-regulation of IRF8 by
siRNA protected OPCs from IFNg-induced apoptosis.
Immunoblots after introduction of siRNA for
IRF8 demonstrated that the employed siRNA only partially
inhibited IRF8 induction by IFNg (Figure. 9B). The OPCs
with reduced IRF8 protein levels to this extent showed no
significant improvement in the viability of OPCs compared
with those transfected with control siRNA at 48 h after
treatment with IFNg (Figure. 9C). Nevertheless, the num-
ber of TMRE
-/DAPI
- preapoptotic OPCs was partially but
significantly decreased in the cultures transfected with
IRF8 siRNA than that in the control cultures at 24 h after
treatment with IFNg (Figure. 9D).
Furthermore, we examined whether IRF8 enhances the
proapoptotic effects of overexpressed IRF1 in OPCs in
the absence of IFNg. OPCs were co-transfected with the
IRF1 expression construct with hrGFP reporter (PCMV-
IE-IRF1-IRES-hrGFP-pA) and an IRF8 expression con-
struct without hrGFP reporter (PCMV-IE-IRF8-pA) by
electroporation to facilitate identification of double
transfected cells (Figure. 10). As far as we could deter-
mine by immunocytochemistry, 96 ± 4% (n = 3) of
hrGFP
+ cells were positive for IRF8 immunoreactivity,
and 85 ± 5% (n = 3) of IRF8
+ cells were hrGFP
+ at 6 h
after transfection, confirming that virtually all hrGFP
+
cells expressed both IRF1 and IRF8 after co-transfection.
When both IRF8 and IRF1 were overexpressed in OPCs
(IRF1+IRF8), preapoptotic (TMRE
-/DAPI
-)c e l l sw e r e
significantly more than those in the OPCs overexpres-
sing IRF1 alone (IRF1+empty) (Figure. 10B), although
there was no statistical significance in reduction of live
transfected cells (hrGFP
+) between the IRF1+empty
and IRF1+IRF8 groups at 24 h after transfection
(Figure 10C). These results indicated that overexpressed
IRF8 protein directly enhances the proapoptotic effects
of IRF1 in OPCs even in the absence of IFNg.
Discussion
Proapoptotic effects of IFNg a n da tm o s tm i n i m a lc y t o -
toxic effects of IFNb on OPCs have been reported pre-
viously [4-9,12,13]. In the present study, however, we
have directly compared effects of IFNg and IFNb on
OPCs in the same in vitro condition, and confirmed a
substantial difference in proapoptotic effects between
the two IFNs. Furthermore, IFNb was not protective
against IFNg-induced OPC apoptosis, despite several
prior reports that IFNb antagonizes IFNg signaling
[39-43]. As far as we could determine by transcriptional
induction of IRF1, simultaneous application of IFNb
failed to reduce IFNg-mediated robust induction of IRF1
[17]. Although the mechanisms underlying the beneficial
therapeutic effects of IFNb on relapsing-remitting MS
are still largely unknown, recent studies have indicated
that IFNb and type I IFN receptor-mediated signaling
limit CNS autoimmunity by regulating innate immune
responses in peripheral tissues [44,45] and the produc-
tion and properties of TH17 cells, a pathogenic T helper
subset largely responsible for CNS autoimmunity [46].
Despite the beneficial effects of IFNb which is further
ensured by far less cytotoxicity of IFNb to OPCs, we
observed that IFNb did inhibit the cell cycle in OPCs,
though to a lesser extent than IFNg.I ti st h u sc o n c e i v a -
ble that, as demonstrated by Trebst et al.[14], IFNb
attenuates the endogenous capability for remyelination,
which is presumably masked by its profound beneficial
effects on the immune system.
Based on the marked difference in proapoptotic effects
between IFNg and IFNb on OPCs, our next aim in this
study was to identify those ISGs responsible for IFNg-
mediated OPC apoptosis. IFNg induces robust and sus-
tained elevation of IRF1, whereas IFNb elicits only a
transient elevation of IRF1, which ends up being unde-
tectable at the protein level at 24 h after treatment, indi-
cating that IRF1 is a candidate for such an ISG [17]. In
support of this, Balabanov’s group has recently reported
that, using a lentiviral expression system, down-regula-
tion of IRF1 by IRF1 shRNA partially protected against
IFNg-induced OPC apoptosis, and that forced expres-
sion of IRF1 reduced the viability of OPCs [18]. We
employed a different forced expression system and a
dominant negative approach in this study, and con-
firmed significant involvement of IRF1 in IFNg-mediated
OPC apoptosis. We further provided direct evidence for
activation of the mitochondrial apoptotic pathway by
overexpression of IRF1 alone. Notably, however, both
approaches used in our study and the study by Balaba-
nov’s group to down-regulate IRF1-mediated transcrip-
tion failed to completely inhibit IFNg-mediated
apoptotic events, suggesting possible functional redun-
dancy of the ISGs involved in IFNg-mediated
Figure 6 Expression constructs used in the study. A,P C M V - I E ,
immediate-early cytomegalovirus promoter; IRF1 DBD, IRF1 DNA
binding domain; IRES, internal ribosome entry site; hrGFP,
humanized Renilla GFP; pA, poly adenylation signal sequence.
B, Fluorescence signals of hrGFP in the transfected cells became
detectable by microscopy as early as 6 h after transfection.
C, Fluorescent imaging demonstrates that the IRF1DN-hrGFP fusion
protein was localized in the nuclei of transfected OPCs.
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Page 10 of 16Figure 7 Overexpressed IRF1 induces OPC apoptosis, whereas overexpressed IRF8 does not. A, OPCs were transfected with the control
vector (PCMV-IE-IRES-hrGFP-pA), the expression construct of rat IRF1 (PCMV-IE-IRF1-IRES-hrGFP-pA), or the expression construct of rat IRF8 (PCMV-
IE-IRF8-IRES-hrGFP-pA) by electroporation. These OPCs were incubated with TMRE and DAPI at 6 and 24 h after transfection and analyzed by flow
cytometry. B, Representative gating scheme of flow cytometric analysis of preapoptotic (TMRE
-/DAPI
-) OPCs in the transfected (hrGFP
+)a n d
untransfected (hrGFP
-) populations at 24 h after transfection with the IRF1 expression construct. Live cells negative for DAPI in the R2 gate were
separated into hrGFP
+ (R3) and hrGFP
- (R4) cells. Preapoptotic OPCs were then counted in the R5 and R6 gated areas in hrGFP
+ (R3) and hrGFP
- (R4)
populations, respectively. C, Number of preapoptotic (TMRE
-/DAPI
-) OPCs in transfected (hrGFP
+) and untransfected (hrGFP
-) populations at 6 and 24 h
after transfection with the control vector, IRF1 expression construct or IRF8 expression construct. D, Reduction in live transfected cells (DAPI
-/hrGFP
+)a t
24 h in the cultures transfected with the control vector, IRF1 expression construct or IRF8 expression construct. Due to the different transfection
efficiencies among the expression constructs, percentages of live transfected (DAPI
-/hrGFP
+) cells in total live (DAPI
-) cells were calculated in each
condition, and are shown as fold changes of the calculated percentages at 6 h after transfection. ** Indicates p < 0.01 (n = 9). E,O v e r e x p r e s s e dI R F 1
and IRF8 were verified by immunoblotting. GFP-positive cell populations in OPC cultures transfected with the expression constructs of rat IRF1 (IRF1-GFP
+)
or IRF8 (IRF8-GFP
+) were separated from GFP-negative cell populations (IRF1-GFP
- and IRF8-GFP
-) with a cell sorter, and subjected to immunoblotting for
IRF1 and IRF8, respectively. Untransfected OPCs cultured with medium alone (C), and medium containing IFNg (100 ng/ml, G)w e r eu s e da sn e g a t i v ea n d
positive controls, respectively.
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Page 11 of 16transcriptional activation leading to apoptosis of OPCs.
Given the structural and functional similarity among
members of the IRF family and their known interac-
tions, transcriptional activity of IRF1 is likely to be mod-
ified or compensated by the other members of the IRF
protein family.
Figure 8 Effects of overexpressed dominant-negative IRF1 and
overexpressed IRF8 on IFNg-induced OPC apoptosis. A, OPCs
were transfected by electroporation with the control vector (PCMV-
IE-IRES-hrGFP-pA), the expression construct of a dominant-negative
form of IRF1 (IRF1DN-hrGFP) which is a fusion protein of IRF1 DNA-
binding domain (IRF1DBD) and hrGFP (PCMV-IE-IRF1DBD/hrGFP-pA),
and the expression construct of rat IRF8 (PCMV-IE-IRF8-IRES-hrGFP-
pA). Cells were cultured with GM for 24 h after transfection, and
then treated with GM alone (control) or GM plus IFNg (100 ng/ml).
At 24 h after treatments, cells were stained with TMRE and DAPI,
and analyzed by flow cytometry as in Figure. 7. B, Number of
preapoptotic (TMRE
-/DAPI
-) OPCs in the cultures subjected to
electroporation with the control vector or the IRF1DN expression
construct at 24 h after treatment with IFNg (100 ng/ml). Transfected
(hrGFP
+) and untransfected (hrGFP
-) populations were analyzed
separately, using the same gatings as in Figure. 7. C, Number of live
transfected cells (DAPI
-/hrGFP
+) in the cultures transfected with the
control vector, IRF1DN expression construct or IRF8 expression
construct after a 24 h IFNg-treatment (48 h after transfection).
Percentages of DAPI
-/hrGFP
+ cells in total live (DAPI
-) cells were
calculated in each condition, and are shown as fold changes of the
percentages just before addition of IFNg (24 h after transfection).
Note that the same percentages of transfected (hrGFP
+) and
untransfected (hrGFP
-) OPC populations died during 24 h after
addition of IFNg in the control group, whereas less and more
transfected OPCs were dead in the IRF1-DN and IRF8 groups,
respectively. ** Indicates p < 0.01 in comparison with the
corresponding data at 24 h (n = 9).
Figure 9 Selective down-regulation of IRF8 by siRNA protects
OPCs from IFNg-induced OPC apoptosis. A, OPCs were
transfected by electroporation with IRF8 siRNA and negative conrol
siRNA. Cells were cultured with GM for 3 h after transfection, and then
treated with GM alone (control) or GM plus IFNg (100 ng/ml). At 24 or
48 h after treatments, cells were subjected to western blotting. MTT
assay, or stained with TMRE and DAPI followed by the flow cytometric
analysis as in Figure. 7. B, Protein levels of IRF8 in the OPCs transfected
with negative control siRNA (Neg siRNA) or IRF8 siRNA were examined
by immunoblotting at 24 h after addition of IFNg (+IFNg, 100 ng/ml).
The untransfected OPCs (No siRNA) treated with IFNg (+IFNg, 100 ng/
ml) or medium alone (C) for 24 h were used as positive and negative
control for IRF1 expression, respectively. B, Viability of the OPCs
transfected with negative control siRNA (control siRNA, open bar) or
IRF8 siRNA (closed bar) was measured by MTT assay at 48 h after
treatment with GM alone (control) or GM plus IFNg (100 ng/ml). C,
Number of preapoptotic (TMRE
-/DAPI
-) OPCs in the cultures subjected
to electroporation with negative control siRNA (control siRNA, open
bar) or IRF8 siRNA (closed bar) at 24 h after treatment with IFNg
(100 ng/ml). ** Indicates p < 0.01 (n = 9).
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file of the IRF family in OPCs stimulated by either IFNg
or IFNb, we found that IRF8 was also up-regulated by
IFNg but not by IFNb. IRF8 was originally identified as
a protein that binds to the ISRE in the promoter region
of the MHC class I gene H-2LD [47], and was believed
to be expressed exclusively in the hematopoietic lineage
(Reviewed in [48]). Our result indicates that OPCs are
also capable of expressing IRF8 in response to IFNg.I n
contrast to overexpression of IRF1, however, overexpres-
sion of IRF8 alone resulted in only transient depolariza-
tion of the mitochondrial membrane in OPCs, but failed
to reduce their viability. More importantly, despite this
weak proapoptotic effect of overexpressed IRF8 itself, it
significantly enhanced the IFNg-induced apoptosis and
proapoptotic effect of overexpressed IRF1 in OPCs even
in the absence of IFNg. Unlike other IRF members, IRF8
is capable of binding to the target DNA motif only fol-
lowing association with IRF1, IRF2 or non-IRF tran-
scription factors such as PU.1 [36,49]. As an example,
IRF8 and IRF1 synergistically induce several genes, such
as IL-12 and iNOS [50,51], in activated macrophages. A
study from Ozato’s group also demonstrated that IRF8
induced by activated STAT1 forms a multiprotein tran-
scriptional complex with other nuclear proteins, which
binds to GAS, and, in turn, potentiates transcriptional
Figure 10 IRF8 enhances the proapoptotic effect of IRF1 in the absence of IFNg. A, OPCs were co-transfected with the following
combinations of expression constructs by electroporation; The control GFP vector (PCMV-IE-IRES-hrGFP-pA) plus the rat IRF8 expression construct
without GFP reporter (PCMV-IE-IRF8-pA) (GFP+IRF8), the rat IRF1 expression construct with GFP reporter (PCMV-IE-IRF1-IRES-hrGFP-pA) plus the rat
IRF8 expression construct without GFP reporter (PCMV-IE-IRF8-pA) (IRF1+IRF8), or PCMV-IE-IRF1-IRES-hrGFP-pA plus the empty vector (PCMV-IE-pA)
(IRF1+empty). These OPCs were incubated with TMRE and DAPI at 6 and 24 h after transfection and analyzed by flow cytometry. B, Number of
preapoptotic (TMRE
-/DAPI
-) OPCs at 24 h after electroporation with GFP+IRF8, IRF1+empty, and IRF1+IRF8. Transfected (hrGFP
+) and untransfected
(hrGFP
-) populations were analyzed separately, using the same gatings as in Figure. 7. ** Indicates p < 0.01 compared with GFP
- (non-transfected)
counterparts, or in comparison between the two groups indicated. C, Reduction in live transfected cells (DAPI
-/hrGFP
+) at 24 h in the cultures
transfected with GFP+IRF8, IRF1+empty, or IRF1+IRF8. Percentages of DAPI
-/hrGFP
+ cells in total live (DAPI
-) cells were calculated in each condition,
and are shown as fold changes of those at 6 h after transfection. N.S. indicates p > = 0.05 between the two groups indicated.
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Page 13 of 16activation of the ISGs in a GAS-dependent manner [52].
Therefore, it is conceivable that, although IRF8 alone is
not sufficient to activate the apoptogenic cascade in
OPCs, IRF8 enhances IFNg-induced OPC apoptosis by
interacting with other transcription factors activated by
IFNg. Indeed, IRF8 is known to function as a proapopto-
tic transcription factor like IRF1. IRF8-deficient mice
are characterized by a myeloproliferative phenotype
resulting in a syndrome similar to human chronic mye-
logenous leukemia [53]. This oncogenic phenotype is
attributable to cytokine hypersensitivity and apoptosis
resistance of IRF8 deficient myeloid progenitor cells
[54]. During differentiation of the myeloid lineage, IRF8
down regulates anti-apoptotic genes such as Bcl-XL,o n e
of anti-apoptotic member of the Bcl-2 family, and
PTPN13, which encodes an inhibitor of Fas-mediated
apoptosis [55,56]. The anti-oncogenic roles of IRF8 are
associated with its proapoptotic function in the other
types of tumors as well. In colon carcinoma cells, IRF8
induced by IFNg sensitizes them to Fas-mediated apop-
tosis, but the silencing of the IRF8 gene by methylation
of its promoter region renders them resistance to IFNg-
mediated apoptosis [57].
Reduction of IRF8 by siRNA failed to enhance viability
of OPCs after treatment with IFNg, although it partially
but significantly decreased the number of preapoptotic
cells. However, we still could not rule out a contribution
of the endogenous IRF8 in the IFNg-induced OPC apop-
tosis, because the transfection of the IRF8 siRNA
resulted in only a partial suppression against the robust
IRF8 induction by IFNg. Together, these results support
the notion that endogenous IRF8 positively regulates the
IFNg-induced OPC apoptosis depending on its induced
dosage.
We previously demonstrated that, unlike OPCs,
mature myelin-producing oligodendrocytes were totally
resistant to IFNg-induced apoptosis [10]. Nevertheless,
IRF1 was similarly induced by IFNg in mature oligo-
dendrocytes compared with OPCs [10,17]. We also
c o n f i r m e dt h a tI F N g induced IRF8 mRNA at similar
levels in both OPCs and mature oligodendrocytes
(Data not shown.). These results indicate that IRF1-
mediated transcriptional activations may be necessary
to activate the apoptotic cascade in OPCs, but are not
sufficient. We speculate that differences in cellular
context between OPCs and mature oligodendrocytes
such as activities of ERK signaling are the other neces-
sary components for IFNg-induced OPC apoptosis as
well [10,58,59].
Conclusions
Conclusions from this study are summarized as follows.
First, unlike IFNg,I F N b is far less capable of inducing
OPC apoptosis. Second, our comprehensive analysis of
the IRF family members in IFNg-a n dI F N b-treated
OPCs identified that IRF1 and IRF8 are preferentially
up-regulated by IFNg. Third, functional analyses of IRF1
and IRF8 revealed that not only IRF1 but also IRF8 con-
tribute to the IFNg-mediated OPC apoptosis. This find-
ing will help us to identify downstream genes involved
in OPC apoptosis. These transcription factors and their
downstream target genes could be potential therapeutic
targets to enhance remyelination in MS.
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